Champions Oncology Inc. Common Stock (CSBR)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Champions Oncology traded at $4.90, giving a $68.2 million market value. The company sells translational oncology research and TumorGraft technology to drug developers and clinicians. The promise is real, but the numbers are not those of a durable franchise. In FY2026, the year ended 2026-04-30, revenue was $59.4 million and net income was a loss of $1.2 million, or EPS of -$0.08. That followed FY2025 net income of $4.7 million on $56.9 million of revenue, and FY2024 net loss of $7.3 million. So the business is a turnaround, as the computed Lynch category says: a loss in the latest year after earlier profits. The latest fiscal Q1 2027, quarter ended 2026-07-31, showed $15.2 million revenue but a $426,000 net loss. Free cash flow was -$6.1 million, and the FairStock FCF yield is -9.0%. The balance sheet gives me little comfort: debt-to-equity is 2.46, while FairStock's Altman Z-Score is -1.57 and its Piotroski F-Score is 2/9. Valuation is not a bargain on asset or cash earnings: at that close, FairStock's P/B is 17.50 and EV/EBITDA is 185.45. Negative earnings make FairStock's P/E meaningless. Revenue has grown, but not enough to prove pricing power or a moat. I would want consistent profits, positive cash generation, and a sturdier balance sheet before calling this a sound value. The low beta of 0.40 and niche platform are not enough to offset the weak financials.

In plain English: Champions Oncology provides research services and technology for cancer drug development and personalized cancer care. The business looks weak: it lost money in its latest full year, is burning cash, and carries a lot of debt. The stock price looks expensive compared with its profits and the value left after subtracting what it owes from what it owns, even though the share price is near the lower end of its past-year range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-31) · fiscal Q2 2026 10-Q (period ended 2025-10-31) · fiscal Q1 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-04-30) · FY2025 10-K (period ended 2025-04-30) · FY2024 10-K (period ended 2024-04-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer